title: [Glycopyrrolate treatment for drooling in an adult with cerebral palsy].
abstract: BACKGROUND
  The aim of the study was to assess the effect of glycopyrrolate on drooling in an adult male patient with cerebral palsy.
  
  
  METHODS
  After a thorough medical examination and consent in writing from his guardian, a baseline sum score for frequency and seriousness of drooling was established over a two-week period in addition to data on shifts of bibs, urination, defecation and observation of behaviour. Glycopyrrolate (1 mg) tablets were then administered, starting with one tablet daily the third week and increasing the daily dose by one tablet per week until a maximum of four tablets during week 6 and four days of week 7, when the daily dose was reduced to two tablets for three days. In the four weeks 8-11, three tablets were given daily. In week 12 the dose was reduced to two tablets and for the weeks 13-15 no glycopyrrolate was given.
  
  
  RESULTS
  As long as the patient received three to four tablets of glycopyrrolate daily, drooling was markedly reduced, and bibs were not necessary on some days. After withdrawal, drooling increased to approximately the same level as before treatment.
  
  
  CONCLUSIONS
  For shorter periods, glycopyrrolate can be given in controlled doses provided that an adequate medical assessment has been undertaken.
authors.affiliation: Modum forskningsgruppe Postboks 75 3371 Vikersund. nperotto@c2i.net
authors.forename: P O
authors.initials: PO
authors.lastname: Neverlien
authors.forename: L
authors.initials: L
authors.lastname: Sørumshagen
authors.forename: T
authors.initials: T
authors.lastname: Eriksen
authors.forename: T
authors.initials: T
authors.lastname: Grinna
authors.forename: H
authors.initials: H
authors.lastname: Kvalshaugen
authors.forename: A B
authors.initials: AB
authors.lastname: Lind
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002547:Cerebral Palsy / Q000150:complications* / Q000503:physiopathology; D006024:Glycopyrrolate / Q000008:administration & dosage*; D006801:Humans; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D012798:Sialorrhea / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
chemical_list: D018727:Muscarinic Antagonists; D006024:Glycopyrrolate